Drugs / CF33-hNIS
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05346484 | May 2022 → Jan 2026 | cholangiocarcinoma, metastatic malignant neoplasm | Imugene Limited | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CF33-hNIS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05346484 ↗ |
| Route | Intravenous | “administered via two routes of administration, intratumoral (IT) or intravenous (IV)” NCT05346484 ↗ |